Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Many Mounjaro users are looking into alternative medications following news of a 170 percent price increase in the UK ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20%, according to a large, international study paid for by Novo Nordisk, the drugmaker behind the product.

Popular weight loss drugs like Wegovy and Ozempic could increase the risk of stomach paralysis as well as several other serious gastrointestinal conditions, according to a study published in JAMA.

By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...